Increased CSF Aβ during the very early phase of cerebral Aβ deposition in mouse models

Abnormalities in brains of Alzheimer's disease (AD) patients are thought to start long before the first clinical symptoms emerge. The identification of affected individuals at this ‘preclinical AD’ stage relies on biomarkers such as decreased levels of the amyloid-β peptide (Aβ) in the cerebros...

Descripción completa

Detalles Bibliográficos
Autores principales: Maia, Luis F, Kaeser, Stephan A, Reichwald, Julia, Lambert, Marius, Obermüller, Ulrike, Schelle, Juliane, Odenthal, Jörg, Martus, Peter, Staufenbiel, Matthias, Jucker, Mathias
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Ltd 2015
Materias:
Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4520655/
https://www.ncbi.nlm.nih.gov/pubmed/25978969
http://dx.doi.org/10.15252/emmm.201505026

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4520655/
https://www.ncbi.nlm.nih.gov/pubmed/25978969
http://dx.doi.org/10.15252/emmm.201505026

Ejemplares similares